science
Senator Introduces Bill to Restrict 340B Drug Discount Program
Sen. Bill Cassidy introduced legislation on June 26, 2026, that would overhaul the federal 340B program by allowing retroactive rebates instead of upfront discounts. The measure would also require hospitals to pass savings to patients and impose limits on contract pharmacies.
FI
upi.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Sen. Bill Cassidy introduced a bill on June 26, 2026, to restrict the federal 340B drug discount program. The legislation would allow drugmakers to provide hospitals with retroactive rebates rather than upfront discounts.
Hospitals could still receive discounts only if they pass the savings directly to patients. The bill would require hospitals to establish a sliding-fee scale for prescription drugs. It would also impose new limits on the contract pharmacies that hospitals use to administer the discounts.
Jeff Vacirca is among the final candidates under consideration by the Trump administration to lead the FDA. Vacirca has served as chief executive officer and chairman of New York Cancer & Blood Specialists since 2008. He holds a medical degree from St.
George’s University and co-founded OneOncology, where he serves on the board of directors. He is also a board member of Caris Life Sciences.
